Advertisement
Canada markets close in 2 hours 26 minutes

  • S&P/TSX

    22,044.44
    +172.48 (+0.79%)
     

  • S&P 500

    5,069.31
    +58.71 (+1.17%)
     

  • DOW

    38,521.65
    +281.67 (+0.74%)
     

  • CAD/USD

    0.7320
    +0.0019 (+0.26%)
     

  • CRUDE OIL

    83.09
    +1.19 (+1.45%)
     

  • Bitcoin CAD

    91,120.40
    +34.73 (+0.04%)
     

  • CMC Crypto 200

    1,433.87
    +19.11 (+1.35%)
     

  • GOLD FUTURES

    2,341.20
    -5.20 (-0.22%)
     

  • RUSSELL 2000

    2,003.91
    +36.44 (+1.85%)
     

  • 10-Yr Bond

    4.5840
    -0.0390 (-0.84%)
     

  • NASDAQ

    15,684.09
    +232.79 (+1.51%)
     

  • VOLATILITY

    16.20
    -0.74 (-4.37%)
     

  • FTSE

    8,044.81
    +20.94 (+0.26%)
     

  • NIKKEI 225

    37,552.16
    +113.55 (+0.30%)
     

  • CAD/EUR

    0.6836
    -0.0014 (-0.20%)
     
MARKETS LIVE BLOG:

STOCKS EXTEND GAINS AS RESULTS SEASON KICKS INTO HIGH GEAR

Tech-focused investors prepare for fresh wave of earnings highlighted by struggling Tesla

CareDx to Report First Quarter 2023 Financial Results

Business Wire
·1 min read

BRISBANE, Calif., May 08, 2023--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced it will report financial results for the first quarter 2023 after market close on Wednesday, May 10, 2023. Company management will host a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.

Individuals interested in listening to the conference call may do so by dialing 1-800-732-8470 for domestic callers or 1-212-231-2912 for international callers. Please reference Conference ID: 22026935. To listen to a live webcast, please visit the investor relations section of CareDx’s website at: investors.caredxinc.com.

About CareDx – The Transplant Company

CareDx, Inc., headquartered in Brisbane, California, is a leading precision medicine solutions company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. CareDx offers testing services, products, and digital healthcare solutions along the pre- and post-transplant patient journey and is the leading provider of genomics-based information for transplant patients. For more information, please visit: www.CareDx.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230508005264/en/

Contacts

CareDx, Inc.
Investor Relations
Greg Chodaczek
investor@caredx.com